An Observational Study in Children With CLN2 Batten Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This is a prospective, longitudinal natural history study to document the progression of ocular manifestations of CLN2 disease among a community-dwelling population of pediatric participants affected by this disease.
Condition or disease
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
CLN2 is a rare disease with limited available ocular natural history data. While current standard of care slows motor degeneration, it is not known to treat the ocular manifestations of disease. This study is planned to document, through prospective data collection, ocular disease progression in children with a clinical presentation consistent with CLN2 Batten disease undergoing current standard of care for their condition. No investigational product is administered in this observational study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children with CLN2 Batten disease undergoing current standard of care for their condition.
A participant is eligible to be included in the study only if all of the following criteria apply:
His or her legal guardian(s) is(are) willing and able to provide them written, signed informed consent.
Has documented diagnosis of CLN2 disease due to TPP1 deficiency, or has a relative clinically diagnosed with CLN2 with the same mutation as the participant
Is currently receiving biweekly ERT treatment with cerliponase alfa
A participant is excluded from the study if any of the following criteria apply:
Has had prior treatment with an adeno-associated virus-based AAV gene therapy
Is currently participating in a clinical trial of investigational product for the treatment of CLN2 disease